PBLS
NASDAQ HealthcareParabilis Medicines, Inc. - Common Stock
Biotechnology
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.
๐ Market Data
| Price | $29.06 |
|---|---|
| Volume | 517,434 |
| Market Cap | 3.55B |
| RSI (14-Day) | 59.6 |
| 52-Week High | $34.47 |
| 52-Week Low | $24.51 |
| Forward P/E | -15.29 |
| Price / Book | -0.17 |
๐ฏ Investment Strategy Scores
PBLS scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (59/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Moon Shot (5/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find PBLS in your text
Paste any article, transcript, or post โ the tool will extract PBLS and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.